Financial Report: AstraZeneca

AstraZeneca

2Q Revenues: $6.7 billion (-21%)

2Q Earnings: $1.6 billion (-19%)

YTD Revenues: $14.0 billion (-16%)

YTD Earnings: $3.3 billion (-23%)

Comments: U.S. revenues were down 29%, with the loss of exclusivity for Seroquel IR accounting for 80% of the revenue decline. Revenue in the Rest of World (ROW) was down 12% in the quarter. Loss of exclusivity on several key brands accounted for 15% of the revenue decline in the quarter. Nexium sales were $949 million (-13% at CER). Seroquel sales were $647 million (-57% at CER). Seroquel IR sales were 277 million (-75% at CER). Crestor sales were 1.6 billion (-5% at CER). Atacand sales were $269 million (-25% at CER). Symbicort sales were $795 million (+3 at CER%).